0001493152-21-026298.txt : 20211026 0001493152-21-026298.hdr.sgml : 20211026 20211026080021 ACCESSION NUMBER: 0001493152-21-026298 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211026 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 211345955 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 8-K 1 form8-k.htm
0001349929 false 0001349929 2021-10-26 2021-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 26, 2021

 

VYANT BIO, INC.

(Exact Name of Company as Specified in its Charter)

 

Delaware   001-35817   04-3462475

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2 Executive Campus

2370 State Route 70, Suite 310

Cherry Hill, NJ 08002

(Address of Principal Executive Offices) (Zip Code)

 

Company’s telephone number, including area code (201) 479-8126

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VYNT   The Nasdaq Capital Market

 

 

 

 

 

 

Item 8.01. Other Events.

 

On October 26, 2021, Vyant Bio, Inc. (the “Company”) announced the appointment of Robert T. Fremeau Jr., Ph.D. as Chief Scientific Officer.

 

Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history of scientific innovation and program leadership at the intersection of target validation, translation and clinical development. As a Scientific Director at Amgen Inc., he led and contributed to multiple teams that advanced small molecules into clinical trials against innovative targets across neurological indications. Throughout his academic career at Duke University and UCSF, Dr. Fremeau made seminal contributions to the first molecular and functional characterization of the receptors and transporters for the biogenic amine and amino acid neurotransmitters. Dr. Fremeau holds numerous patents and has authored over 65 peer-reviewed publications in prestigious scientific journals including: Science, Nature, Neuron, PNAS, Journal of Medicinal Chemistry, and Journal of Neuroscience.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

As described above, the following exhibits are furnished as part of this report:

 

Exhibit 99.1 - Press release, dated October 26, 2021. 

Exhibit 104 - Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VYANT BIO, INC.
       
    By: /s/ John A. Roberts
    Name: John A. Roberts
    Title: President and Chief Executive Officer
       
Date: October 26, 2021    

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D.

as Chief Scientific Officer

 

Cherry Hill, N.J., October 26, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer.

 

Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history of scientific innovation and program leadership at the intersection of target validation, translation and clinical development. As a Scientific Director at Amgen Inc., he led and contributed to multiple teams that advanced small molecules into clinical trials against innovative targets across neurological indications. Throughout his academic career at Duke University and UCSF, Dr. Fremeau made seminal contributions to the first molecular and functional characterization of the receptors and transporters for the biogenic amine and amino acid neurotransmitters. Dr. Fremeau holds numerous patents and has authored over 65 peer-reviewed publications in prestigious scientific journals including Science, Nature, Neuron, PNAS, Journal of Medicinal Chemistry, and Journal of Neuroscience.

 

“We are thrilled to have Dr. Fremeau join the Vyant Bio team,” said Jay Roberts, President and CEO of Vyant Bio. “Dr. Fremeau’s extensive experience with scientific research and drug discovery will be invaluable to us as we develop the preclinical and translational strategy for driving a portfolio of therapeutic candidates from early discovery to human proof-of-concept. We are looking forward to having Dr. Fremeau work across the Vyant Bio organization with colleagues and partners in translational biology, chemical sciences, and computational and data sciences to ensure that an innovative and rigorous multidisciplinary approach is taken. He will be instrumental in helping us to achieve our ultimate goal of building the company into a drug discovery engine that finds impactful medicines to address the needs of patients around the world”.

 

“I look forward to becoming part of the Vyant Bio team and actively participating in the further development of the Company’s innovative and novel methods for determining drug efficacy and in initiating the discovery and development of new therapeutics to treat an array of neurology and oncology conditions,” stated Dr. Fremeau. “What a privilege to lead the efforts to establish a world-leading scientific advisory board comprised of industry leaders in neurology, oncology and protein sciences, to help drive our therapeutic pipeline and corporate mission forward.”

 

 

 

 

ABOUT VYANT BIO, INC.

 

Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT) has developed a drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise. Through multiple in silico, in vitro, and in vivo modalities, Vyant Bio rapidly identifies and designs small and large molecule therapeutics that are derisked in human biology much earlier, and have lower costs and failure rates compared to traditional discovery platforms. The Company is focused on efficiently discovering neurology and oncology drugs and, going forward, plans to file two investigational new drug applications annually. Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia. The Company has five state-of-the-art labs and a scientific team with world experts in key areas who have been involved in over 200 investigational new drug applications and over 50 CNS and oncology studies and trials.

 

For more information, please visit or follow Vyant Bio at:

 

Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio

 

Forward Looking Statements:

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.

 

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.

 

Investor Contact:

 

Jennifer K. Zimmons, Ph.D., MBA
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514

 

###

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 vynt-20211026.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 vynt-20211026_def.xml XBRL DEFINITION FILE EX-101.LAB 6 vynt-20211026_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 vynt-20211026_pre.xml XBRL PRESENTATION FILE XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001349929 2021-10-26 2021-10-26 iso4217:USD shares iso4217:USD shares 0001349929 false 8-K 2021-10-26 VYANT BIO, INC. DE 001-35817 04-3462475 2 Executive Campus 2370 State Route 70, Suite 310 Cherry Hill, NJ 08002 (201) 479-8126 false false false false false Common Stock VYNT NASDAQ XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Oct. 26, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 26, 2021
Entity File Number 001-35817
Entity Registrant Name VYANT BIO, INC.
Entity Central Index Key 0001349929
Entity Tax Identification Number 04-3462475
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Executive Campus
Entity Address, Address Line Two 2370 State Route 70,
Entity Address, Address Line Three Suite 310
Entity Address, City or Town Cherry Hill,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08002
City Area Code (201)
Local Phone Number 479-8126
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol VYNT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vyantbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm vynt-20211026.xsd vynt-20211026_lab.xml vynt-20211026_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "vynt-20211026_lab.xml" ] }, "presentationLink": { "local": [ "vynt-20211026_pre.xml" ] }, "schema": { "local": [ "vynt-20211026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VYNT", "nsuri": "http://vyantbio.com/20211026", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-10-26to2021-10-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://vyantbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-10-26to2021-10-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://vyantbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001493152-21-026298-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-026298-xbrl.zip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